• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过多组学聚类鉴定卵巢癌的预后亚型及FXYD6的作用

Identification of prognostic subtypes and the role of FXYD6 in ovarian cancer through multi-omics clustering.

作者信息

Ma Boyi, Ren Chenlu, Gong Yun, Xi Jia, Shi Yuan, Zhao Shuhua, Yin Yadong, Yang Hong

机构信息

Department of Obstetrics and Gynecology, Xijing Hospital, The Fourth Military Medical University, Shaanxi, China.

出版信息

Front Immunol. 2025 Mar 18;16:1556715. doi: 10.3389/fimmu.2025.1556715. eCollection 2025.

DOI:10.3389/fimmu.2025.1556715
PMID:40170843
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11958163/
Abstract

BACKGROUND

Ovarian cancer (OC), as a malignant tumor that seriously endangers the lives and health of women, is renowned for its complex tumor heterogeneity. Multi-omics analysis, as an effective method for distinguishing tumor heterogeneity, can more accurately differentiate the prognostic subtypes with differences among patients with OC. The aim of this study is to explore the prognostic subtypes of OC and analyze the molecular characteristics among the different subtypes.

METHODS

We utilized 10 clustering algorithms to analyze the multi-omics data of OC patients from The Cancer Genome Atlas (TCGA). After that, we integrated them with ten different machine-learning methods in order to determine high-resolution molecular subgroups and generate machine-learning-driven characteristics that are both resilient and consensus-based. Following the application of multi-omics clustering, we were able to identify two cancer subtypes (CSs) that were associated with the prognosis. Among these, CS2 demonstrated the most positive predictive outcome. Subsequently, five genes that constitute the machine learning (ML)-driven features were screened out by ML algorithms, and these genes possess a powerful predictive ability for prognosis. Subsequently, the function of FXYD Domain-Containing Ion Transport Regulator 6 (FXYD6) in OC was analyzed through gene knockdown and overexpression, and the mechanism by which it affects the functions of OC was explored.

RESULTS

Through multi-omics analysis, we ascertained that the high-risk score group exhibits a poorer prognosis and lack of response to immunotherapy. Moreover, this group is more prone to display the "cold tumor" phenotype, with a lower likelihood of benefiting from immunotherapy. FXYD6, being a crucial differential molecule between subtypes, exerts a tumor-promoting effect when knocked down; conversely, its overexpression yields an opposite outcome. Additionally, we discovered that the overexpression of FXYD6 can induce ferroptosis in OC cells, implying that a low level of FXYD6 in OC cells can safeguard them from ferroptosis. Insightful and more precise molecular categorization of OC can be achieved with a thorough examination of multi-omics data. There are significant consequences for clinical practice stemming from the discovery of risk scores since they provide a useful tool for early prognosis prediction as well as the screening of candidates for immunotherapy.

摘要

背景

卵巢癌(OC)作为一种严重危及女性生命健康的恶性肿瘤,以其复杂的肿瘤异质性而闻名。多组学分析作为区分肿瘤异质性的有效方法,能够更准确地鉴别出OC患者中存在差异的预后亚型。本研究旨在探索OC的预后亚型,并分析不同亚型之间的分子特征。

方法

我们运用10种聚类算法对来自癌症基因组图谱(TCGA)的OC患者的多组学数据进行分析。之后,我们将它们与10种不同的机器学习方法相结合,以确定高分辨率的分子亚组,并生成基于弹性和一致性的机器学习驱动特征。在应用多组学聚类之后,我们能够识别出两种与预后相关的癌症亚型(CSs)。其中,CS2表现出最积极的预测结果。随后,通过机器学习算法筛选出构成机器学习(ML)驱动特征的五个基因,这些基因对预后具有强大的预测能力。随后,通过基因敲低和过表达分析了含FXYD结构域的离子转运调节因子6(FXYD6)在OC中的功能,并探讨了其影响OC功能的机制。

结果

通过多组学分析,我们确定高风险评分组预后较差且对免疫治疗无反应。此外,该组更容易表现出“冷肿瘤”表型,从免疫治疗中获益的可能性较低。FXYD6作为亚型之间的关键差异分子,敲低时具有促肿瘤作用;相反,其过表达则产生相反的结果。此外,我们发现FXYD6的过表达可诱导OC细胞发生铁死亡,这意味着OC细胞中低水平的FXYD6可保护它们免于铁死亡。通过对多组学数据的深入研究,可以实现对OC更有见地和更精确的分子分类。风险评分的发现对临床实践具有重要意义,因为它们为早期预后预测以及免疫治疗候选者的筛选提供了有用的工具。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98a6/11958163/9c3ef4369e10/fimmu-16-1556715-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98a6/11958163/04575c79c2eb/fimmu-16-1556715-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98a6/11958163/4d2c5982223b/fimmu-16-1556715-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98a6/11958163/92341310286f/fimmu-16-1556715-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98a6/11958163/9b53a2266074/fimmu-16-1556715-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98a6/11958163/30583cb87f05/fimmu-16-1556715-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98a6/11958163/9c3ef4369e10/fimmu-16-1556715-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98a6/11958163/04575c79c2eb/fimmu-16-1556715-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98a6/11958163/4d2c5982223b/fimmu-16-1556715-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98a6/11958163/92341310286f/fimmu-16-1556715-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98a6/11958163/9b53a2266074/fimmu-16-1556715-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98a6/11958163/30583cb87f05/fimmu-16-1556715-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98a6/11958163/9c3ef4369e10/fimmu-16-1556715-g006.jpg

相似文献

1
Identification of prognostic subtypes and the role of FXYD6 in ovarian cancer through multi-omics clustering.通过多组学聚类鉴定卵巢癌的预后亚型及FXYD6的作用
Front Immunol. 2025 Mar 18;16:1556715. doi: 10.3389/fimmu.2025.1556715. eCollection 2025.
2
Multi-omics characterization and machine learning of lung adenocarcinoma molecular subtypes to guide precise chemotherapy and immunotherapy.肺腺癌分子亚型的多组学特征分析及机器学习以指导精准化疗和免疫治疗
Front Immunol. 2024 Nov 28;15:1497300. doi: 10.3389/fimmu.2024.1497300. eCollection 2024.
3
Integrating immune multi-omics and machine learning to improve prognosis, immune landscape, and sensitivity to first- and second-line treatments for head and neck squamous cell carcinoma.整合免疫多组学和机器学习以改善头颈部鳞状细胞癌的预后、免疫格局以及对一线和二线治疗的敏感性。
Sci Rep. 2024 Dec 28;14(1):31454. doi: 10.1038/s41598-024-83184-y.
4
RETRACTED: Refining molecular subtypes and risk stratification of ovarian cancer through multi-omics consensus portfolio and machine learning.撤回:通过多组学共识组合和机器学习优化卵巢癌的分子亚型和风险分层。
Environ Toxicol. 2025 Mar;40(3):E1-E16. doi: 10.1002/tox.24222. Epub 2024 Mar 13.
5
Integrated multi-omics analysis and machine learning to refine molecular subtypes, prognosis, and immunotherapy in lung adenocarcinoma.整合多组学分析和机器学习以细化肺腺癌的分子亚型、预后和免疫治疗。
Funct Integr Genomics. 2024 Jun 27;24(4):118. doi: 10.1007/s10142-024-01388-x.
6
Multiomics evaluation and machine learning optimize molecular classification, prediction of prognosis and immunotherapy response for ovarian cancer.多组学评估和机器学习优化了卵巢癌的分子分类、预后预测和免疫治疗反应。
Pathol Res Pract. 2025 May;269:155925. doi: 10.1016/j.prp.2025.155925. Epub 2025 Mar 29.
7
Combining multi-omics analysis with machine learning to uncover novel molecular subtypes, prognostic markers, and insights into immunotherapy for melanoma.将多组学分析与机器学习相结合,以揭示黑色素瘤的新型分子亚型、预后标志物以及免疫治疗相关见解。
BMC Cancer. 2025 Apr 7;25(1):630. doi: 10.1186/s12885-025-14012-3.
8
Integrated multi-omics analysis identifies a machine learning-derived signature for predicting prognosis and therapeutic vulnerability in clear cell renal cell carcinoma.整合多组学分析确定了一种基于机器学习的特征,用于预测透明细胞肾细胞癌的预后和治疗易感性。
Life Sci. 2025 Feb 15;363:123396. doi: 10.1016/j.lfs.2025.123396. Epub 2025 Jan 12.
9
Advancing lung adenocarcinoma prognosis and immunotherapy prediction with a multi-omics consensus machine learning approach.采用多组学生物学共识机器学习方法改善肺腺癌预后和免疫治疗预测。
J Cell Mol Med. 2024 Jul;28(13):e18520. doi: 10.1111/jcmm.18520.
10
Unveiling the role of PANoptosis-related genes in breast cancer: an integrated study by multi-omics analysis and machine learning algorithms.揭示PAN细胞焦亡相关基因在乳腺癌中的作用:一项通过多组学分析和机器学习算法的综合研究。
Breast Cancer Res Treat. 2025 May;211(1):35-50. doi: 10.1007/s10549-025-07620-x. Epub 2025 Jan 28.

本文引用的文献

1
Radiomics and radiogenomics: extracting more information from medical images for the diagnosis and prognostic prediction of ovarian cancer.放射组学和放射基因组学:从医学影像中提取更多信息用于卵巢癌的诊断和预后预测。
Mil Med Res. 2024 Dec 14;11(1):77. doi: 10.1186/s40779-024-00580-1.
2
Targeted and cytotoxic inhibitors used in the treatment of breast cancer.用于治疗乳腺癌的靶向性和细胞毒性抑制剂。
Pharmacol Res. 2024 Dec;210:107534. doi: 10.1016/j.phrs.2024.107534. Epub 2024 Dec 2.
3
Evolving landscape of detection and targeting miRNA/epigenetics for therapeutic strategies in ovarian cancer.
卵巢癌治疗策略中用于检测和靶向微小RNA/表观遗传学的不断演变的格局。
Cancer Lett. 2024 Nov 29;611:217357. doi: 10.1016/j.canlet.2024.217357.
4
Treatment Strategies for Advanced Endometrial Cancer According to Molecular Classification.根据分子分类的晚期子宫内膜癌治疗策略。
Int J Mol Sci. 2024 Oct 24;25(21):11448. doi: 10.3390/ijms252111448.
5
Mitochondrial-Derived Peptide MOTS-c Suppresses Ovarian Cancer Progression by Attenuating USP7-Mediated LARS1 Deubiquitination.线粒体衍生肽 MOTS-c 通过减弱 USP7 介导的 LARS1 去泛素化抑制卵巢癌进展。
Adv Sci (Weinh). 2024 Nov;11(43):e2405620. doi: 10.1002/advs.202405620. Epub 2024 Sep 25.
6
Current status and research directions in acute myeloid leukemia.急性髓细胞白血病的现状与研究方向。
Blood Cancer J. 2024 Sep 19;14(1):163. doi: 10.1038/s41408-024-01143-2.
7
Top advances of the year: Targeted therapy for lung cancer.年度重大进展:肺癌靶向治疗。
Cancer. 2024 Oct 1;130(19):3239-3250. doi: 10.1002/cncr.35423. Epub 2024 Jun 21.
8
Immune cell infiltration and prognostic index in cervical cancer: insights from metabolism-related differential genes.免疫细胞浸润与宫颈癌预后指标:代谢相关差异基因的启示
Front Immunol. 2024 May 22;15:1411132. doi: 10.3389/fimmu.2024.1411132. eCollection 2024.
9
Novel frontiers in urogenital cancers: from molecular bases to preclinical models to tailor personalized treatments in ovarian and prostate cancer patients.泌尿生殖系统癌症的新前沿:从分子基础到临床前模型,为卵巢癌和前列腺癌患者制定个性化治疗方案。
J Exp Clin Cancer Res. 2024 May 15;43(1):146. doi: 10.1186/s13046-024-03065-0.
10
The roles of FXYD family members in ovarian cancer: an integrated analysis by mining TCGA and GEO databases and functional validations.FXYD家族成员在卵巢癌中的作用:通过挖掘TCGA和GEO数据库及功能验证进行的综合分析
J Cancer Res Clin Oncol. 2023 Dec;149(19):17269-17284. doi: 10.1007/s00432-023-05445-z. Epub 2023 Oct 9.